Patents by Inventor Hugh Sampson

Hugh Sampson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7820175
    Abstract: The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of food allergy and food allergy related symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of food allergy-related symptoms in a patient in need thereof.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: October 26, 2010
    Assignee: Herbal Spring, LLC
    Inventors: Xiu-Min Li, Hugh A. Sampson
  • Publication number: 20100166802
    Abstract: The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.
    Type: Application
    Filed: October 2, 2009
    Publication date: July 1, 2010
    Inventors: Michael J. Caplan, H. Kim Bottomly, Howard B. Sosin, A. Wesley Burks, Hugh A. Sampson
  • Publication number: 20090111702
    Abstract: The present invention is directed to materials and methods that may be used in diagnosing and/or characterizing allergies. More specifically, the specification describes methods and compositions for making and using a plurality of peptides having allergen epitopes that may be used in immunoassays e.g., microarray-based immunoassays to predict the severity of an allergic response.
    Type: Application
    Filed: March 22, 2005
    Publication date: April 30, 2009
    Applicant: MOUNT SINAI SCHOOL OF MEDICINE Office of Industrial Liason
    Inventors: Hugh A. Sampson, Wayne G. Shreffler, Kirsten Beyer
  • Patent number: 7485708
    Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: February 3, 2009
    Assignee: University of Arkansas
    Inventors: A. Wesley Burks, Jr., Gary A. Bannon, Hugh A. Sampson, Ricki M. Helm, J. Steven Stanley, Patrick A. Rabjohn
  • Publication number: 20080317878
    Abstract: The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of food allergy and food allergyrelated symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of food allergy-related symptoms in a patient in need thereof.
    Type: Application
    Filed: March 14, 2005
    Publication date: December 25, 2008
    Inventors: Xiu-Min Li, Hugh A. Sampson
  • Publication number: 20080254484
    Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.
    Type: Application
    Filed: May 30, 2008
    Publication date: October 16, 2008
    Inventors: Murtaza E. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
  • Publication number: 20080213298
    Abstract: The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of asthma and asthma-related symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of asthmatic symptoms in a patient in need thereof.
    Type: Application
    Filed: March 14, 2005
    Publication date: September 4, 2008
    Inventors: Xiu-Min Li, Hugh A. Sampson, Ming-Chun Weng
  • Patent number: 7381556
    Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: June 3, 2008
    Assignee: Monsanto Technology LLC
    Inventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
  • Publication number: 20080010700
    Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.
    Type: Application
    Filed: June 28, 2007
    Publication date: January 10, 2008
    Inventors: Murtaza Alibhai, James Astwood, Charles McWherter, Hugh Sampson
  • Publication number: 20070213507
    Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE-binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than-within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined.
    Type: Application
    Filed: January 10, 2006
    Publication date: September 13, 2007
    Inventors: A. Burks, Gary Bannon, Hugh Sampson, Ricki Helm, Gael Cockrell, J. Stanley, Nina King
  • Patent number: 7238511
    Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: July 3, 2007
    Assignee: Monsanto Technology LLC
    Inventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
  • Publication number: 20060206962
    Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.
    Type: Application
    Filed: September 7, 2005
    Publication date: September 14, 2006
    Inventors: Murtaza Alibhai, James Astwood, Charles McWherter, Hugh Sampson
  • Patent number: 6943002
    Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of palatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: September 13, 2005
    Assignee: Monsanto Technology LLC
    Inventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
  • Publication number: 20050063994
    Abstract: The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.
    Type: Application
    Filed: July 26, 2004
    Publication date: March 24, 2005
    Inventors: Michael Caplan, Kim Bottomly, Howard Sosin, A. Burks, Hugh Sampson
  • Publication number: 20050048576
    Abstract: The present invention is directed to methods for predicting or diagnosing a hazelnut-induced systemic reaction, and for methods for treating such a reaction.
    Type: Application
    Filed: June 2, 2004
    Publication date: March 3, 2005
    Inventors: Hugh Sampson, Kirsten Beyer
  • Publication number: 20040216187
    Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding.
    Type: Application
    Filed: September 9, 2003
    Publication date: October 28, 2004
    Applicant: MONSANTO TECHNOLOGY LLC
    Inventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
  • Publication number: 20030202980
    Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino acid within the protein, preferably a hydrophobic residue towards the center of the IgE epitope, to eliminate IgE binding. Additionally or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemically, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE eitopes and disrupting one or more disulfide bonds of the natural allergen.
    Type: Application
    Filed: March 18, 2002
    Publication date: October 30, 2003
    Inventors: Michael J. Caplan, Howard B. Sosin, Hugh Sampson, Gary A. Bannon, A. Wesley Burks, Gael Cockrell, Cesar M. Compadre, Cathie Connaughton, Ricki M. Helm, Nina E. King, Randall A. Kopper, Soheila J. Maleki, Patrick A. Rabjohn, David S. Shin, J. Steven Stanley
  • Patent number: 6639054
    Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: October 28, 2003
    Assignee: Monsanto Technology LLC
    Inventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
  • Publication number: 20030194399
    Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding.
    Type: Application
    Filed: January 5, 2001
    Publication date: October 16, 2003
    Applicant: MONSANTO TECHNOLOGY LLC
    Inventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
  • Patent number: 6630176
    Abstract: The present invention provides herbal compositions that can prevent or reduce the severity, intensity, or duration of allergic and/or asthmatic symptoms and/or can prevent or delay the development of an allergic or asthmatic response to an antigen. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutical carriers or excipients, and may be administered prior to, during, or after the development of allergic or asthmatic symptoms in sensitized individuals. Alternatively or additionally, the compositions may be administered prior to sensitization to a particular antigen; preferably substantially concurrently with exposure to the antigen.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: October 7, 2003
    Assignee: Mount Sinai School of Medicine of New York University
    Inventors: Xiu-Min Li, Hugh A. Sampson